Vincenzo Puppo

Istituto di Sessuologia Clinica

Papers

1

Total Citations

14

H-Index

1

About

Vincenzo Puppo is a prominent researcher in the fields of sexual medicine, urology, and public health, with a particular focus on female sexual dysfunction and pharmacological interventions. His most notable contribution is his critical analysis of the U.S. Food and Drug Administration’s approval of Addyi (flibanserin) for hypoactive sexual desire disorder (HSDD), a landmark paper that has garnered 14 citations and sparked widespread debate on the efficacy, safety, and regulatory processes surrounding treatments for female sexual health. Puppo’s work challenges conventional narratives, emphasizing the need for rigorous evidence-based standards and highlighting the sociocultural and biological complexities of desire disorders. His research has significantly influenced clinical guidelines and public discourse, bridging gaps between pharmacology, patient advocacy, and ethical considerations in drug approval. With a career dedicated to advancing understanding of sexual dysfunction, Puppo remains a key voice in shaping how researchers and clinicians approach treatment paradigms, ensuring that patient outcomes and scientific integrity remain at the forefront of sexual medicine.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
US Food and Drug Administration Approval of Addyi (Flibanserin) for Treatment of Hypoactive Sexual Desire Disorder
14 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 1
🏛 Institutions: Istituto di Sessuologia Clinica

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago